Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Daiichi Sankyo Inc. |
---|---|
Information provided by: | Daiichi Sankyo Inc. |
ClinicalTrials.gov Identifier: | NCT00151814 |
Determine single dose PK of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Olmesartan medoxomil |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Open-Label Study of the Single-Dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension |
Estimated Enrollment: | 24 |
Study Start Date: | October 2005 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 12 Months to 16 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
Little Rock, Arkansas, United States | |
United States, California | |
La Jolla, California, United States | |
United States, Kentucky | |
Louisville, Kentucky, United States | |
United States, Missouri | |
Kansas City, Missouri, United States | |
United States, Ohio | |
Cleveland, Ohio, United States |
Responsible Party: | Daiichi Sankyo ( Michael Melino, PhD ) |
Study ID Numbers: | CS0866-A-U102 |
Study First Received: | September 8, 2005 |
Last Updated: | April 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00151814 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Olmesartan PK in children |
Angiotensin II Type 1 Receptor Blockers Vascular Diseases Olmesartan medoxomil Cardiovascular Agents |
Antihypertensive Agents Angiotensin II Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Vascular Diseases Olmesartan medoxomil |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Hypertension |